Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Zydus Lifesciences Ltd (ZYDU)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
987.90 +34.35    +3.60%
11:00:02 - Closed. Currency in INR ( Disclaimer )
  • Volume: 2,760,348
  • Bid/Ask: 987.90 / 990.00
  • Day's Range: 951.05 - 992.00
Type:  Equity
Market:  India
ISIN:  INE010B01027 
S/N:  ZYDUSLIFE
Zydus Lifesciences 987.90 +34.35 +3.60%

ZYDU Income Statement & Profits

 
Assess the Cadila Healthcare income statement, view the company's financial performance across their assets and liabilities. Select to view either quarterly or annual data.
AnnualQuarterly
InvestingPro Advanced Income Statement
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Revenue 45052 43688 51396 46677
Revenue 43437 42586 50528 52121
Other Revenue, Total 1615 1102 868 -5444
Cost of Revenue, Total 14685 14738 16744 18566
Gross Profit 30367 28950 34652 28111
Total Operating Expenses 36182 34891 37870 38751
Selling/General/Admin. Expenses, Total 8173 7529 7304 17232
Research & Development - - - 3597
Depreciation / Amortization - - - -
Interest Expense (Income) - Net Operating -198 -87 -181 -233
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 13522 12711 14003 -411
Operating Income 8870 8797 13526 7926
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - - - 804
Other, Net -949 -1509 19 2146
Net Income Before Taxes 9819 10306 13507 4976
Provision for Income Taxes 2138 2264 2161 1372
Net Income After Taxes 7681 8042 11346 3604
Minority Interest - 22081 - 21725
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 7678 8017 10879 2988
Total Extraordinary Items 218 -10 -10 -22
Net Income 7896 8007 10869 2966
Total Adjustments to Net Income -218 10 10 22
Income Available to Common Excluding Extraordinary Items 7678 8017 10879 2988
Dilution Adjustment 218 -10 -10 -22
Diluted Net Income 7678 8017 10879 2988
Diluted Weighted Average Shares 1012.31 1012.26 1012.01 1012.29
Diluted EPS Excluding Extraordinary Items 7.58 7.92 10.75 2.95
DPS - Common Stock Primary Issue - - - 6
Diluted Normalized EPS 6.06 6.34 7.97 5.68
* In Millions of INR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ZYDU Price Commentary

Write your thoughts about Zydus Lifesciences Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Akshath Suvarna
Akshath Suvarna Jan 12, 2024 9:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
great buy ,best time to enter
Irfan ali
Irfan ali Dec 16, 2023 10:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
After 655 coming breakout target 695 to 710
Hardik Vora
Hardik Vora Mar 12, 2022 9:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What Is The Target For Next Week?
Kshetrapal Sahu
Kshetrapal Sahu Jan 25, 2022 21:51
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is ne bhut so ko barbaad kra benkelode share ne
Jay JinDaL
Jay JinDaL Jan 16, 2022 18:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
3rd class stock
SHIVA shiva
SHIVA shiva Jan 07, 2022 14:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Magic starts....
Paramjit Lamba
Paramjit Lamba Aug 25, 2021 3:47
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to fly in September and early October. BUY at dips, preferably between 500 or below to 550 levels to make 100 to 150 plus gains.
Javgal Kanth
Javgal Kanth Aug 25, 2021 3:47
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good
Javgal Kanth
Javgal Kanth Aug 24, 2021 23:30
Saved. See Saved Items.
This comment has already been saved in your Saved Items
As YoY revenue is up, possibility of more revenue growth due to covid vaccine approval may result in QoQ net profit uptrend shows good returns in medium term. Buy on every decline below 500 for good returns in long term.
sandeep sheregar
sandeep sheregar May 26, 2021 6:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it may reaches upper circuit in few days. vaccine related mou done with govt. best pharma stock in coming days
Pankaj Kumar
Pankaj Kumar May 25, 2021 7:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
make position for June 10% gain is coming
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email